Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

The Veterans Affairs Hepatitis C Treatment Considerations

Yee, Helen S., PharmD1,2,3,4,5; Burton, Mary Jane, MD6,7; Belperio, Pamela S., PharmD8; Morgan, Timothy R., MD4,9,10

American Journal of Gastroenterology: February 2019 - Volume 114 - Issue 2 - p 185–188
doi: 10.1038/s41395-018-0231-4
THE RED SECTION

1San Francisco VA Health Care System, San Francisco, CA, USA;

2University of California, San Francisco, San Francisco, CA, USA;

3University of the Pacific, Stockton, CA, USA;

4National VA Hepatitis C Resource Center, Washington, DC, USA;

5VA HIV, Hepatitis, and Related Conditions Program in the Office of Specialty Care Services, Washington, DC, USA;

6G.V. Sonny Montgomery VA Medical Center, Jackson, MS, USA;

7University of Mississippi Medical Center, Jackson, MS, USA;

8VA Office of Patient Care Services/Population Health, Washington, DC, USA;

9VA Long Beach Healthcare System, Long Beach, CA, USA;

10University of California, Irvine, Irvine, CA, USA.

Correspondence: Helen S. Yee, PharmD. E-mail: helen.yee@va.gov. or Timothy R. Morgan, MD. E-mail: timothy.morgan@va.gov.

Received April 30, 2018

Accepted July 19, 2018

© The American College of Gastroenterology 2019. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website